{
    "root": "5f3a03d8-3583-4214-baa9-4fe16d2628d2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "sirolimus"
    },
    "value": "20250321",
    "ingredients": [
        {
            "name": "SIROLIMUS",
            "code": "W36ZG6FT64"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "SOYBEAN PHOSPHATIDYLCHOLINE",
            "code": "1T6N4D9YV6"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SUNFLOWER OIL MONO/DIGLYCERIDES",
            "code": "HS7EB0C1ZH"
        },
        {
            "name": "SOY ACID",
            "code": "HBA528N3PW"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "ASCORBYL PALMITATE",
            "code": "QN83US2B0N"
        },
        {
            "name": "TOCOPHEROL",
            "code": "R0ZB2556P8"
        }
    ],
    "indications": "Sirolimus oral solution is     an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ     rejection in patients aged ≥13 years receiving renal transplants: Patients at low- to moderate-immunologic risk: Use         initially with cyclosporine (CsA) and corticosteroids. CsA withdrawal is         recommended 2-4 months after transplantation ( 1.1 ). Patients at high-immunologic risk: Use in         combination with CsA and corticosteroids for the first 12 months following         transplantation ( 1.1 ). Safety and efficacy of CsA withdrawal has not been established in high risk patients ( 1.1 , 1.2 , 14.3 ). Sirolimus  oral solution is an mTOR inhibitor indicated     for the treatment of patients with lymphangioleiomyomatosis ( 1.3 ).",
    "contraindications": "Sirolimus oral solution is to be administered orally once daily, consistently with or without food [see Dosage and Administration (2.5), Clinical Pharmacology (12.3)].",
    "warningsAndPrecautions": "Since sirolimus oral solution is not absorbed through the skin, there are no special precautions. However, if direct contact of the oral solution occurs with the skin or eyes, wash skin thoroughly with soap and water; rinse eyes with plain water.\n                   Do not use sirolimus oral solution after the expiration date. The expiration date refers to the last day of that month.",
    "adverseReactions": "Sirolimus is contraindicated in patients with a hypersensitivity to sirolimus [see Warnings and Precautions (5.4)]."
}